The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.
 
Neha K. Reddy
No Relationships to Disclose
 
Jason Roszik
No Relationships to Disclose
 
David Carl Norris
Stock and Other Ownership Interests - Precision Methodologies
 
Roman Groisberg
Honoraria - Regeneron
Speakers' Bureau - Rockpointe CME; TotalCME
 
Niamh Coleman
No Relationships to Disclose
 
Omar Alhalabi
No Relationships to Disclose
 
Ethan B. Ludmir
No Relationships to Disclose
 
Cullen M. Taniguchi
Honoraria - Xerient
Consulting or Advisory Role - Accuray
Patents, Royalties, Other Intellectual Property - Oral amifostine for radio protection of the intestinal tract; PHD inhibitors for radio protection of the GI Tract
 
Ishwaria Mohan Subbiah
Consulting or Advisory Role - MedImmune (I)
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I)
Travel, Accommodations, Expenses - Bayer (I); MedImmune (I); Novartis (I); PharmaMar (I)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape